Athar Ansari, MD, DTM&H, MRCP (UK), FACC

790-west-orange-avenue-066_web

BIOGRAPHY:

· Director – California Heart & Vascular Clinic
· Performed over 10,000 cardiac, endovascular, and peripheral vascular interventions
·  Presenter on cutting edge topics in Cardiovascular and Endovascular Diseases, in the US and internationally.
· 25 years’ broad based experience in internal medicine and cardiology, in the US and internationally.
· Helped establish and directed Scripps Clinic’s first fellowship program in Peripheral Vascular Interventions in 2008 and trained the first Scripps fellows in peripheral intervention.

BOARD CERTIFICATIONS:

· Diplomate, American Board of Vascular Medicine, 2007
· Diplomate, American Board of Endovascular Medicine, 2007
· Diplomate, American Board of Interventional Cardiology, 2002
· Diplomate, American Board of Cardiovascular Diseases, 1997
· Diplomate, American Board of Internal Medicine, 1994
· Member, Royal College of Physicians, MRCP (UK), 1988
· Diploma, Tropical Medicine and Hygiene, DTM&H (UK), 1987

HOSPITALS:

· Scripps Green Hospital/Scripps Clinic, La Jolla, CA
· Sharp Chula Vista Medical Center, San Diego, CA
· Scripps Memorial Hospital, La Jolla, CA

Consulting Cardiologist on staff at:

· El Centro Regional Medical Center, El Centro, CA
· Pioneers Memorial Hospital, Brawley, CA

FELLOWSHIPS:

· Cedars Sinai Medical Center, Los Angeles, CA
· Cardiology 1994
· Interventional Cardiology 1995
· Transesophageal Echocardiography
· Good Samaritan Hospital, Los Angeles, CA 1996

RESIDENCY:
United States

· Internal Medicine, The Mayo Clinic, Rochester, MN 1992

United Kingdom

· Registrar/Clinical Tutor Cardiology (University of Aberdleen, Scotland)  1990
· Registrar Infectious Diseases/Clinical Tutor (University Of Aberdleen Scotland) 1989
· Registrar Diabetes/Internal Medicine 1988  West Suffolk Hospital Bury St. Edmunds
· Senior House Officer, Birmingham Heartland Hospital 1984-87
(Medical Rotation)
Internal Medicine / Rheumatology
Cardiology
Metabolic Medicine
Infectious Diseases
Nephrology
Thoracic Medicine
Infectious Diseases
(Clinical Attachment)

Pakistan 

· (Mayo Hospital, Lahore) Resident, General Surgery 1983
· Internal Medicine 1982

LICENSURE:

· California, UK, Pakistan


EDUCATION:

· King Edward Medical College, Lahore, Pakistan
·
· MBBS 1981
· B.S. 1976


CURRENT INTERESTS:

· Development and testing of new cardiovascular and endovascular intervention devices.
· Research, teaching and protocol development in interventional cardiology and peripheral vascular disease
· Live case demonstration in interventional cardiology and endovascular diseases.

 

RESEARCH:

· Observation on Rheumatic Heart Disease in Pakistan (Pakistan Heart Journal Vol. 22, Issue I Jan – Mar ’89 pp 2-7)
High Dose Oral Fluconazole For Oralpharyngeal Candidiasis in AIDS (Journal of Anti-microbial Chemotherapy 1990 Vol. 25 pp 720-721) from 1990 to 1992.
· Role of Transesophageal Echocardiography in Endocarditis (In collaboration with the Mayo Clinic, Rochester, MN.)
Piperacillian / Tazabactam in Treatment of Serious Acute Soft Tissue Infections. Drugs Exp Clin Res 187-90 In 1992.
· Role of Dobutamine Echocardiography in Assessment of Myocarcdial Viability in 1994.
· Abnormal Myocardial Perfussion Single Photon Emission Computed Tomography and Normal Coronary Arteriogram:
The Role of Intracoronary Vascular Ultrasound in Providing Diagnostic Confirmation. (American Heart Journal 130/ (1) 182-186 July 1995) Kiat H, Ansari A, Berman D.
· Co-Investigator TRITON-TIMI 38 (Principal Investigator: John Gordon, M.D.) – A comparison of (CS-747) and clopidogrel in acute coronary syndrome subjects who are to undergo percutaenous coronary intervention.
Sponsored by Eli Lilly and Company. Study began 11/01/2005 at Sharp Memorial Hospital.
· Co-Investigator SPIDER (Principal Investigator: John Gordon, M.D.): SVG Protection in a distal embolic protection randomized trial at Sharp Memorial Hospital – 02/20/2004 through 03/31/2005
· Co- Investigator STEEPLE Study – XRP 4563/4001
(Principal Investigator – Brian Jaski, MD)
An international phase 2 to 3, stratified, randomized, open-label, parallel-group clinical trial to evaluate the safety and efficacy of a single intravenous bolus of enoxaparin versus intravenous unfractionated heparin in patients undergoing non-emergent Percutanous Coronary Intervention at Sharp Memorial Hospital 09/01/2004 through 02/28/2005
· Coordinator ISIS III Trial (International Study on Infarct Survival) University of Aberdeen, Scotland 1989 – 1990

FELLOWSHIP LAB RESEARCH:

· Assessment of thrombosis using Techoflex coating on a nitinol stent in a rabbit model in 1994.
· Comparison of Johnson & Johnson stent and HARTS device for thrombosis in a porcine model in 1994.
· Drug Eluting Stents Impact on Coronary Artery Disease (Punjab Institute of Cardiology, March 2002)
· New Trends in Interventional Cardiology (Hong Kong, April 2004)
· Challenges in Interventional Cardiology (New Delhi, India, March 2005)